A phase 3 therapy, zoliflodacin, has shown to be noninferior in a late stage trial. The therapy's manufacturer, Innoviva Speciality Therapeutics, is presenting data at this week's ID Week. The company's CMO David Altarac, MD, offers some insights on the therapy and the timeline for filing the paperwork for prospective FDA approval.
GS-1720 could offer a weekly dosing option for individuals living with HIV, supported by a good safety profile with no serious adverse events, which has led to the initiation of a Phase 2 study.
A serious adverse event of motor neuropathy reported in September 2024 has resulted in a hold on the investigational new drug application.
At this week’s ID Week, Ferring Pharmaceuticals shares results from its outpatient study examining its treatment, Rebyota, for the prevention of recurrence.
The Hawaii Department of Health released a report detailing the alarming link between hepatitis C and premature mortality in the state.
The Gilead capsid inhibitor has been shown to have less adverse events compared to another PrEP, and the company plans to begin regulatory filings for approval before the end of this year.
It is important to recognize this organ that has multiple life-enhancing functions.
The study indicates that targeting the sympathetic nervous system could improve CDI management, as a novel multi-target mRNA vaccine was shown to protect mice from lethal doses.
The state's outbreak has reached over 100 confirmed cases among dairy herds, contributing to a national total of 300 outbreaks across 14 states.
Last year, several cases were identified in American patients traveling to Mexico to receive cosmetic surgery. The source of transmission was discovered, and one of the investigators, Sarah Bergbower DCLS, MS, MLS (ASCP)CM, discusses her part with 1 of the cases.
The Xpert HCV assay facilitates rapid HCV diagnosis in nonclinical settings, aiding high-risk populations like those under community supervision.
This week, recent investigations link contaminated ice machines to Burkholderia multivorans infections, the hepatitis treatment market is projected to grow to USD 30.2 billion by 2032, 2020 guidelines recommend targeting specific AUC levels for optimizing vancomycin therapy, and more
In our latest roundtable series, the discussion addressed Long COVID prevalence, underreporting, accurate diagnosis, and emphasized that Long COVID serves as an umbrella term.
A NIH-funded study focused on analyzing the Wuhan strain in unvaccinated patients with COVID-19. Results showed those with certain blood types seemed to fare worse significantly increasing their risk for cardiovascular events and mortality.
Despite evidence of their effectiveness in reducing hospitalization and mortality rates, many older individuals remain untreated, with recent studies highlighting significant disparities in treatment access and adherence.
A holistic, multifaceted approach with a variety of stakeholders are needed to address antimicrobial resistance (AMR). The recent UN meeting on this topic looked to bring together government leaders, industry, and public health officials to discuss strategies regarding the global health crisis.
A new study finds that 1.4 million people aged 12-59 with current hepatitis C (HCV) infection, including over a third of them without a history of injection drug use.
The ideal parameter for vancomycin monitoring is the area under the curve, which can be calculated using pharmacokinetic equations or Bayesian software.
The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus-related lower respiratory tract disease in older adults over three seasons.
Over the past four years, an investigation across California hospitals has linked ice and water use in clinical settings to potential infections.
The global hepatitis treatment market is more than a financial figure; it is a key area in the effort to combat the silent disease that impacts millions around the world.
The pharmaceutical industry faces challenges when investing in new antibiotics, which emphasizes the need for regulatory reforms, incentives, and collaborative efforts between government, healthcare organizations, and private companies. The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies.
People can now take the Healgen Rapid Check COVID-19/Flu A&B Antigen Test in their homes without a prescription.
More food recalls, including eggs, guacamole, Sriracha, and vegetables, were issued due to health risks from contamination, prompting consumer action nationwide.
Basilea Pharmaceutica says its investigational therapy, fosmanogepix, is being studied for candidemia and invasive candidiasis.
Some FDA recalls announced this past week involve various food products, such as veggie straws and sprouts, prompting consumers to remain aware of potential health risks.
Forty percent of the dose of the PCV 13 vaccine, but not of the PCV 10 or lower dose, was found noninferior to full doses when immunizing infants in Kenya.
Healthcare workers receiving additional COVID-19 vaccine doses had fewer ongoing symptoms, a new test differentiates bacterial from viral infections, CDC reports 10 deaths linked to ongoing listeria outbreak, and more this week from Contagion.
The pharmaceutical company said there were no safety issues associated with the decision.
Moderna has begun its study examining its investigational norovirus vaccine, mRNA-1403, to determine its efficacy, safety and immunogenicity.
